Paternot room at Agora Cancer Research Centre, CHUV, Rue du Bugnon 25A, Lausanne
Dr. Olaf Ritzeler, Director, Rare Diseases External Innovation, Global Business Development & Licensing, Sanofi
Matthias Grossmann, VP, Parexel Early Phase Scientific Affairs
Dr. Andrew Galazka, MD, Senior VP, Head of Global Medical Excellence at Merck
Dr. Jens Wuerthner, Head of Clinical Development, ADC Therapeutics
Dr. Justin Devine, Chief Medical Officer, Synexa Group Life Sciences
Claudia Graeve, VP Health Advances
Pantelis Vlachos, Principal Strategic Consultant, Cytel Inc
Philippe Menu, McKinsey & Company
Christian Fehr, Relationship Manager Primary Markets, and Valeria Ceccarelli, Head Primary Markets, SIX
Dr. Victor Cheng, Vice President, Technical, Parexel Consulting
Agora Cancer Research Centre, CHUV
Rue du Bugnon 25A
Lausanne Metro M2, direction “Croisette”, stop: “CHUV” (1 min. walking distance)
CHUV Parking, Avenue de Beaumont 25, 1012 Lausanne (3 min. walking distance)
The Swiss Biotech Association is launching the Swiss biotech Insight event series, designed to cover a portfolio of topics mirroring the biopharma product life cycle, namely from ideation and research to commercialization and patient benefit. The three main areas covered are discovery, development and commercialization.
At the first event of the Insight series, we join forces with Parexel to address major clinical trial strategy challenges, including the growing complexity of trials, changing regulations, spiraling costs, and patient access. The meeting will explore the impact of real world data science, adaptive clinical trial design, biomarkers and more.
Please note that we may keep your personal details for the purpose of contacting you in the future on topics related to the Swiss Biotech Association. Photos, audio and video recordings take place at the event to support public communication activities.
By submitting the registering form, you agree to this use of your personal data and pictures.